RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETES

Aim. To evaluate efficacy of endovascular treatment in patients with diabetes, operated with biodegradable vascular endoprostheses and everolimus eluting stents.Material and methods. Primarily, 143 patients were selected into the study. Then 125 patients included and randomized to 2 groups. Patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Z. Kh. Shugushev, D. A. Maksimkin, Yu. S. Vorob'eva, A. G. Chepurnoj, G. I. Veretnik, A. G. Fajbushevich
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2016-09-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/913
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849341484641288192
author Z. Kh. Shugushev
D. A. Maksimkin
Yu. S. Vorob'eva
A. G. Chepurnoj
G. I. Veretnik
A. G. Fajbushevich
author_facet Z. Kh. Shugushev
D. A. Maksimkin
Yu. S. Vorob'eva
A. G. Chepurnoj
G. I. Veretnik
A. G. Fajbushevich
author_sort Z. Kh. Shugushev
collection DOAJ
description Aim. To evaluate efficacy of endovascular treatment in patients with diabetes, operated with biodegradable vascular endoprostheses and everolimus eluting stents.Material and methods. Primarily, 143 patients were selected into the study. Then 125 patients included and randomized to 2 groups. Patients of I group (n=57) underwent implantation biodegradable vascular endoprostheses, and the II group (n=68) — coronary stents eluting everolimus. For the control of biodegradable endoprostheses implantation optical coherent tomography was used, that was performed at the end of intervention and in long-term follow-up by 12 months. Results. Totally, 63 biodegradable vascular endoprostheses implanted to the patients of I group, and 102 everolimus coated stents to II group patients. Mean diameter of implanted endoprostheses in group I was — 2,88±0,06 mm, and in group II — 2,68±0,12 mm (р>0,05). Technical success of intervention was 100% in both groups. Total number of serious cardiovascular complications during in-patient phase was 3,5% and 2,94% in groups, respectively (p>0,05). Long-term results were followed-up in 41 patient from group I and in 52 from group II. In 12 months survival rate was 100%. Prevalence of non-fatal MI among I and II group patients was 4,9% and 3,8%, resp. (p>0,05). The reason was progression of atherosclerotic process in other arteries. Restenosis prevalence that required new intervention on target lesion was 2,4% and 1,9%, resp. (p>0,05). Late thrombosis in long-term follow-up was not marked in both groups. Late loss of intrinsic lumen of the vessel, by the data of optical coherent tomography was 0,14±0,19 mm and 0,12±0,23 mm, respectively, for groups I and II (р>0,05).Conclusion. Biodegradable vascular endoprostheses in CHD patients with diabetes and mostly involvement of middle and distal segments of coronary arteries, showed equal efficacy and safety, with everolimus coated stents, in 12 months after intervention.
format Article
id doaj-art-c8de443236e54fd593de2836247b2231
institution Kabale University
issn 1560-4071
2618-7620
language Russian
publishDate 2016-09-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-c8de443236e54fd593de2836247b22312025-08-20T03:43:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202016-09-0109192410.15829/1560-4071-2016-9-19-24766RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETESZ. Kh. Shugushev0D. A. Maksimkin1Yu. S. Vorob'eva2A. G. Chepurnoj3G. I. Veretnik4A. G. Fajbushevich5Peoples' Friendship University of Russia, Moscow; N. A. Semashko Central Clinical Hospital №2 of "RGD", MoscowPeoples' Friendship University of Russia, Moscow; N. A. Semashko Central Clinical Hospital №2 of "RGD", MoscowPeoples' Friendship University of Russia, MoscowN. A. Semashko Central Clinical Hospital №2 of "RGD", MoscowPeoples' Friendship University of Russia, MoscowPeoples' Friendship University of Russia, MoscowAim. To evaluate efficacy of endovascular treatment in patients with diabetes, operated with biodegradable vascular endoprostheses and everolimus eluting stents.Material and methods. Primarily, 143 patients were selected into the study. Then 125 patients included and randomized to 2 groups. Patients of I group (n=57) underwent implantation biodegradable vascular endoprostheses, and the II group (n=68) — coronary stents eluting everolimus. For the control of biodegradable endoprostheses implantation optical coherent tomography was used, that was performed at the end of intervention and in long-term follow-up by 12 months. Results. Totally, 63 biodegradable vascular endoprostheses implanted to the patients of I group, and 102 everolimus coated stents to II group patients. Mean diameter of implanted endoprostheses in group I was — 2,88±0,06 mm, and in group II — 2,68±0,12 mm (р>0,05). Technical success of intervention was 100% in both groups. Total number of serious cardiovascular complications during in-patient phase was 3,5% and 2,94% in groups, respectively (p>0,05). Long-term results were followed-up in 41 patient from group I and in 52 from group II. In 12 months survival rate was 100%. Prevalence of non-fatal MI among I and II group patients was 4,9% and 3,8%, resp. (p>0,05). The reason was progression of atherosclerotic process in other arteries. Restenosis prevalence that required new intervention on target lesion was 2,4% and 1,9%, resp. (p>0,05). Late thrombosis in long-term follow-up was not marked in both groups. Late loss of intrinsic lumen of the vessel, by the data of optical coherent tomography was 0,14±0,19 mm and 0,12±0,23 mm, respectively, for groups I and II (р>0,05).Conclusion. Biodegradable vascular endoprostheses in CHD patients with diabetes and mostly involvement of middle and distal segments of coronary arteries, showed equal efficacy and safety, with everolimus coated stents, in 12 months after intervention.https://russjcardiol.elpub.ru/jour/article/view/913diabetesbiodegradable vascular endoprostheseseverolimus coated stents
spellingShingle Z. Kh. Shugushev
D. A. Maksimkin
Yu. S. Vorob'eva
A. G. Chepurnoj
G. I. Veretnik
A. G. Fajbushevich
RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETES
Российский кардиологический журнал
diabetes
biodegradable vascular endoprostheses
everolimus coated stents
title RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETES
title_full RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETES
title_fullStr RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETES
title_full_unstemmed RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETES
title_short RESULTS OF BIODEGRADABLE VASCULAR ENDOPROSTHESES IMPLANTATION IN ISCHEMIC HEART DISEASE PATIENTS WITH TYPE 2 DIABETES
title_sort results of biodegradable vascular endoprostheses implantation in ischemic heart disease patients with type 2 diabetes
topic diabetes
biodegradable vascular endoprostheses
everolimus coated stents
url https://russjcardiol.elpub.ru/jour/article/view/913
work_keys_str_mv AT zkhshugushev resultsofbiodegradablevascularendoprosthesesimplantationinischemicheartdiseasepatientswithtype2diabetes
AT damaksimkin resultsofbiodegradablevascularendoprosthesesimplantationinischemicheartdiseasepatientswithtype2diabetes
AT yusvorobeva resultsofbiodegradablevascularendoprosthesesimplantationinischemicheartdiseasepatientswithtype2diabetes
AT agchepurnoj resultsofbiodegradablevascularendoprosthesesimplantationinischemicheartdiseasepatientswithtype2diabetes
AT giveretnik resultsofbiodegradablevascularendoprosthesesimplantationinischemicheartdiseasepatientswithtype2diabetes
AT agfajbushevich resultsofbiodegradablevascularendoprosthesesimplantationinischemicheartdiseasepatientswithtype2diabetes